Tata Memorial Centre

India's position as the world's third largest producer and core supplier of generic drugs plays a pivotal role in the global pharmaceutical sector and brings significant economic benefits to global healthcare systems, particularly in the United States. At the Indian Leaders' Summit 2024, Union Health Minister Punya Salila Srivastava made it clear that India's influence in the global pharmaceutical industry is far-reaching and not only in terms of numbers - India has the highest number of US FDA-approved pharmaceutical plants, accounting for 25% of the global total. There are also economic benefits - medicines made in India saved the US healthcare system a whopping $219 billion in 2022, and a cumulative $1.3 trillion between 2013 and 2022. At the US-India Strategic Partnership Forum, the Secretary of the Alliance further highlighted India's outstanding contribution in vaccine production, noting that India produces nearly half of the world's vaccines, especially out of the 8 billion doses produced globally last year, India alone contributed 4 billion doses, hence its reputation as the "pharmacy of the world". To further improve the standard of care, India has implemented medical education reforms and replaced outdated regulations with the National Medical Boards Act, which has facilitated an increase in the number of medical and nursing colleges and effectively alleviated the shortage of health professionals. India's health minister said the country is committed to developing a health workforce that can meet domestic needs as well as contribute to global health. From an economic perspective, India's out-of-pocket costs in the health sector as a percentage of total health expenditure have declined by 25% from 2013-14 to 2021-22, demonstrating the continued optimization of the health system and the reduction of the burden on the people. On health cooperation, there is a strong partnership between India and the United States, especially in the areas of epidemic preparedness, disease surveillance and antimicrobial resistance. Through cooperation between the National Centers for Disease Control (NCDC) and the U.S. Centers for Disease Control and Prevention (CDC), such as programs such as the Field Epidemiology Training Program (FETP), the two countries have trained more than 200 epidemic Intelligence Service officers, and more than 50 officers are undergoing training. India and the US have also launched the Bio-5 Alliance Strategic Framework to optimize the biopharmaceutical supply chain. In 2023, the two countries joined forces to advance cancer research, launching the US-India Cancer Moonshot Dialogue, focusing on biomedical cooperation, especially cervical cancer research. The initiative has not only partnered with Indian institutions such as AIIMS and Tata Memorial Hospital, but has also expanded into the Four Cancers Moonshot Initiative and allocated $7.5 million for cancer diagnosis in the Indo-Pacific region. India has also committed to provide 40 million doses of vaccines to support cancer prevention efforts under GAVI and Quad programmes. Initiatives such as the India-US Health Dialogue will continue to make more progress in disease surveillance and pandemic preparedness. The Indian Health minister expressed optimism that the two countries will enhance global health security by advancing research, technology transfer and capacity building through public-private partnerships and joint vaccine programmes.

The pro-oxidant tablet has shown a 30% effectiveness in preventing cancer. White Bear studio / Shutterstock.com. India’s Tata Institute of Fundamental Research (TIFR) has announced the development of a new pro-oxidant tablet, combining resveratrol and copper (R+Cu), that has the potential to prevent the recurrence of cancer. More than a decade of research at the Tata Memorial Centre has resulted in the creation of this tablet which will be priced at around Rs100 ($1.2), Indian media publication NDTV has reported. The institute’s findings suggest that cancer cell remnants, known as cell-free chromatin particles (cfChPs), can induce cancer in healthy cells, leading to new tumour formation. The R+Cu tablet, when ingested, produces oxygen radicals within the stomach. These radicals are rapidly absorbed into the bloodstream, where they target and destroy cfChPs, hindering the process of metastasis—the spread of cancer cells to other body parts. See Also: EMA awards double validation for Daiichi Sankyo and AstraZeneca’s cancer ADC Memorial Sloan Kettering Cancer Center in artificial intelligence: theme innovation strategy The tablet also reduces the toxicity associated with chemotherapy and diminishes the overall side effects of cancer treatment by around 50%. It has shown 30% effectiveness in preventing cancer. Its potential extends to the treatment of cancers including pancreatic, oral and lung. Tata Memorial Hospital senior cancer surgeon Dr Rajendra Badve stated: “Tata doctors were working on this tablet for almost a decade. “The tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI). TIFR scientists have applied to FSSAI to approve this tablet. “This tablet will be available everywhere for just Rs100.” The institute plans to make the tablet available from June/July 2024 for cancer patients following approval from the Indian regulator.

Session conducted by Dr. Rupa Renganathan, who performed India's first breast cancer cryoablation procedure with ProSense®; Expert interview with Dr. Hania Bednarski, who has performed cryoablation breast procedures since 2014 CAESAREA, Israel, Feb. 27, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced ProSense® was featured in a number of sessions, including one titled "Minimal access imaging guided therapies: cryoablative therapies in breast pathologies," at the fourth Breast Imaging & Interventional Techniques (BRIIT) conference at Tata Memorial Centre in Mumbai, India on February 24, 2024. Breast cryoablation expert Dr. Hania Bednarksi also joined one session virtually to provide her valuable experience as a ProSense® user. ProSense® has regulatory approval and is marketed and sold in India through IceCure's distributor, Novomed Ltd. "We have been very active in India and appreciate Dr. Renganathan's initiative inleading the cryoablation education section with ProSense® at BRIIT and Dr. Bednarski for sharing her extensive experience with ProSense®," stated IceCure CEO Eyal Shamir. "Members of IceCure's clinical and marketing team were at the conference to support for the education process and our in-country distributor. We received high levels of interest in procuring ProSense® systems from doctors, clinics and hospitals." Dr. Renganathan commented, "Since the first ProSense® procedure that I conducted about eight months ago at Kovai Medical Center, there has been growing global interest in cryoablation. Therefore, my presentation at BRIIT was well timed, as I was able to share the benefits of cryoablation with a large number of doctors from around the country, at Tata Memorial Centre, widely regarded as one of the leading cancer centers in South Asia." "I have been performing breast cryoablation procedures since 2014 and am currently conducting one to three procedures per week using ProSense® with positive results," stated Dr. Bednarski. "I am honored to have been asked to share my experiences with my colleagues in India. Cryoablation provides clinicians with a new choice in the treatment of breast tumors, and I'm delighted to support its use around the world." About ProSense® The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedure for breast tumors. About IceCure Medical IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China. Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on March 29, 2023, and other documents filed with or furnished to the SEC which are available on the SEC's website, . The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Logo: IR Contact: Email: [email protected] Michael Polyviou Phone: 732-232-6914 Todd Kehrli Phone: 310-625-4462 SOURCE IceCure Medical